Chief Financial Officer · Akero Therapeutics, Inc. (AKRO)

William (PFO)

FY2022 is the first fiscal year CompBrief holds for William (PFO) as a named executive officer of Akero Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,149,643

Salary $452,000Stock awards $824,425

2nd of 4 named executive officers at Akero Therapeutics by FY2022 total.

4 named officers on file for Akero Therapeutics, FY2022

William (PFO)’s pay file — $29

  • 1 fiscal year of pay, line by line
  • AKRO’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Akero Therapeutics’s whole pay program stands against its peers

  • Akero Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AKRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A).

Free

Get William (PFO)’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

William (PFO) compensation by year

Akero Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Akero Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$452,000
Bonus$0
Stock awards$824,425
Option awards$2,556,818
Non-equity incentive$316,400
Pension and deferred compensation$0
All other$0
Total$4,149,643

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akero Therapeutics, Inc. DEF 14A filed April 28, 2025, accession 0000950170-25-058964, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Akero Therapeutics, Inc. filed document, accession 0000950170-25-058964. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

Akero Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Andrew ChengPresident and Chief Executive Officer$10,446,243
William (PFO) · this pageChief Financial Officer$4,149,643
Jonathan YoungChief Operating Officer$4,144,543
Catriona YaleChief Development Officer$4,136,043

The full Akero Therapeutics compensation record

free company brief

This page is one person within Akero Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Akero Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

William (PFO)'s compensation dossier · One-time report. No refunds.